ÂÜÀòÂÒÂ×

Gregg Strohmeier is an experienced pharmaceutical professional currently serving as Director at Keros Therapeutics and as Sr. Principal Scientist at EyePoint Pharmaceuticals, focusing on the development of sustained release platforms in the ocular space. Previous roles include Principal Scientist at Johnson & Johnson, leading multiple programs in a program manager capacity, and Principal Scientist at Momenta Pharmaceuticals, where responsibilities included serving as CMC lead for significant biosimilars and generics. Additionally, experience spans senior scientist positions at Alexion Pharmaceuticals and Synageva BioPharma, with extensive work in formulation development, lyophilization, and CMC activities. Gregg Strohmeier holds an MBA from Boston University, a Ph.D. in Biochemistry from Boston University School of Medicine, and a B.S. in Biochemistry from the University of Rochester.